Home / Central Data Catalog / FRESH-PEF3195-EN
central

Velcade: study of real-life use

France, 2004 - 2006
Reference ID
FRESH-PEF3195-en
Producer(s)
Annie;FOURRIER-REGLAT, Nicholas;MOORE
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
45
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Study activities
  • Access policy
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF3195-en
    Title

    Velcade: study of real-life use
    Abbreviation or Acronym

    VESUVE (beta)
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Oncology health theme
    Hematology health theme
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    Multiple myeloma Velcade® Bortezomib survival conditions of use pharmacoepidemiology cohort Department of Pharmacology Bordeaux

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patients initiating Bortezomib treatment between 1 May 2004 and April 30 2006 (whether or not treatment is continued); Patient unexposed to bortezomib, including during a clinical trial or temporary use authorization; Patient followed by a hospital physician having agreed to participate in the study; Patient not participating in a clinical trial; Patient not objecting to data collection","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Annie;FOURRIER-REGLAT
    Nicholas;MOORE
    Producers
    Name Role
    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) sponsor
    UNIVERSITE DE BORDEAUX sponsor
    Funding Agency/Sponsor
    Name
    JANSSEN CILAG (JANSSEN - JOHNSON & JOHNSON - JOHNSON & JOHNSON INNOVATIVE MEDICINE)

    Study authorization

    Agency
    Agency name
    CNIL

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)','Through independent healthcare practitioners']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2004-01-01 2006-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"Transcription","vocab":"CESSDA"},"value":"Converting or copying information into a structured record"}

    Study activities

    Study activities
    Type
    primary evaluation
    Description
    Health event/morbidity Health event/mortality Health care consumption and services

    Access policy

    Notes

    Ownership of study data was the subject of an agreement between the University of Bordeaux Segalen and the pharmaceutical company.

    Data Access

    Availability Status

    {"value":"To be defined","extLink":[]}

    Contacts

    Contacts
    Name Email
    Annie;FOURRIER-REGLAT annie.fourrier-reglat@u-bordeaux.fr
    Nicholas;MOORE nicholas.moore@u-bordeaux.fr
    Back to Catalog